Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

05 juin 2024 16h18 HE | Source: Robbins LLP

AKRO STOCKHOLDERS - Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Akero Therapeutics, Inc. Class Action

Robbins LLP is Investigating Allegations that Akero Therapeutics, Inc. (AKRO) Misled Investors Regarding the Viability of its Trial Drug Candidate
16 mai 2024 16h15 HE | Source: Robbins LLP

Robbins LLP Reminds Investors of AKRO of the Pending Lead Plaintiff Deadline in the Akero Therapeutics, Inc. Class Action

Robbins LLP is Investigating Allegations that Akero Therapeutics, Inc. (AKRO) Misled Investors Regarding the Viability and Efficacy of its Trial Drug Candi
07 mai 2024 15h06 HE | Source: Robbins LLP

AKRO Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Against Akero Therapeutics, Inc.

Robbins LLP is Investigating Allegations that Akero Therapeutics, Inc. (AKRO) Misled Investors Regarding the Viability and Efficacy of its Trial Drug Candi
30 avr. 2024 00h42 HE | Source: Robbins LLP

Stockholder Alert: Robbins LLP Informs Investors of the Class Action Filed Against Akero Therapeutics, Inc. (AKRO)

Robbins LLP is Investigating Allegations that Akero Therapeutics, Inc. (AKRO) Misled Investors Regarding the Viability and Efficacy of its Trial Drug Candi